We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Oxford Biomedica Plc | LSE:OXB | London | Ordinary Share | GB00BDFBVT43 | ORD 50P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-2.00 | -0.98% | 203.00 | 202.00 | 203.00 | 208.00 | 200.00 | 202.00 | 259,276 | 16:35:17 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medicinal Chems,botanicl Pds | 139.99M | -45.16M | -0.4676 | -4.32 | 195.09M |
TIDMOXB
RNS Number : 7223Z
Oxford Biomedica PLC
25 May 2021
PDMR Dealing
Oxford, UK - 25 May 2021: Oxford Biomedica plc ("Oxford Biomedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, was informed on 24 May 2021, that Nicholas Page, Chief Operations Officer of the Group, exercised 4,119 DBP (2019) options at nil cost, and sold all the resulting ordinary shares at 1128p per share. Following this transaction Nicholas Page continues to hold 89,436 options over ordinary shares.
The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares sold.
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Nicholas Page ----------------------------- ----------------------------------- 2. Reason for the notification ------------------------------------------------------------------ a) Position/status Chief Operations Officer ----------------------------- ----------------------------------- b) Initial notification/ Initial Notification amendment ----------------------------- ----------------------------------- 3. Details of the Issuer ------------------------------------------------------------------ a) Name Oxford BioMedica plc ----------------------------- ----------------------------------- b) LEI code 213800S1GVQNXQ15K851 ----------------------------- ----------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ------------------------------------------------------------------ a) Description of Options over ordinary Shares of 50 the financial pence each instrument ISIN: GB00BDFBVT43 Identification code ----------------------------- ----------------------------------- b) Nature of the Exercise of options transaction ----------------------------- ----------------------------------- c) Currency GBP - British pound ----------------------------- ----------------------------------- d) Price(s) and volumes(s) Price(s) Volume(s) Nil 4,119 ---------- ----------------------------- ----------------------------------- e) Aggregated information 4,119 * Aggregate volume Nil Nil * Price * Aggregated total ----------------------------- ----------------------------------- f) Date of the transaction 2021-05-21 ----------------------------- ----------------------------------- g) Place of the transaction Outside a trading venue ----------------------------- ----------------------------------- 1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Nicholas Page ----------------------------- ----------------------------------- 2. Reason for the notification ------------------------------------------------------------------ a) Position/status Chief Operations Officer ----------------------------- ----------------------------------- b) Initial notification/ Initial Notification amendment ----------------------------- ----------------------------------- 3. Details of the Issuer ------------------------------------------------------------------ a) Name Oxford BioMedica plc ----------------------------- ----------------------------------- b) LEI code 213800S1GVQNXQ15K851 ----------------------------- ----------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ------------------------------------------------------------------ a) Description of Ordinary Shares of 50 pence each the financial ISIN: GB00BDFBVT43 instrument Identification code ----------------------------- ----------------------------------- b) Nature of the Disposal transaction ----------------------------- ----------------------------------- c) Currency GBP - British pound ----------------------------- ----------------------------------- d) Price(s) and volumes(s) Price(s) Volume(s) GBP11.28 4,119 ---------- ----------------------------- ----------------------------------- e) Aggregated information 4,119 * Aggregate volume GBP11.28 GBP46,462.32 * Price * Aggregated total ----------------------------- ----------------------------------- f) Date of the transaction 2021-05-21 ----------------------------- ----------------------------------- g) Place of the transaction London Stock Exchange, Main Market (XLON) ----------------------------- -----------------------------------
-Ends-
For further information, please contact: Oxford Biomedica plc: Tel: +44 (0)1865 783 000 Natalie Walter, Company Secretary
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector(R) ), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a three year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 670 people. Further information is available at www.oxb.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHGIGDUGDDDGBU
(END) Dow Jones Newswires
May 25, 2021 04:21 ET (08:21 GMT)
1 Year Oxford Biomedica Chart |
1 Month Oxford Biomedica Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions